Anadrol (Oxymetholone)
FDA ApprovedOral Anabolic Steroid | Extreme Mass & Strength
Community Research
Join others researching Anadrol — share findings, ask questions, and learn from real experiences
Anadrol (oxymetholone) is one of the most potent oral anabolic steroids ever developed, originally synthesized in the 1960s by Syntex Pharmaceuticals. It was FDA-approved for the treatment of anemias caused by deficient red blood cell production, including aplastic anemia, myelofibrosis, and anemia associated with chronic kidney disease. Anadrol is a DHT-derived compound with a 17-alpha alkylated structure that allows oral bioavailability at the cost of significant hepatic strain. In performance enhancement contexts, it is regarded as the single most powerful oral steroid for rapid mass and strength gains, capable of producing dramatic weight increases of 10-15+ pounds in the first few weeks of use. Despite being a DHT derivative that does not aromatize via the aromatase enzyme, Anadrol produces notable estrogenic side effects including water retention and gynecomastia through a poorly understood mechanism believed to involve direct activation of estrogen receptors. This makes estrogen management uniquely challenging compared to other anabolic steroids.
Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme. However, oxymetholone and its metabolites are believed to directly activate the estrogen receptor, producing estrogenic effects such as water retention and gynecomastia without the involvement of aromatase. This is a critical clinical distinction because aromatase inhibitors (such as anastrozole or letrozole) are ineffective at controlling Anadrol-related estrogenic side effects. The compound also stimulates erythropoietin (EPO) production, significantly increasing red blood cell mass, which is the basis for its FDA-approved indication in anemias. Additionally, oxymetholone inhibits sex hormone-binding globulin (SHBG), increasing the proportion of free testosterone and other anabolic hormones in circulation.
Molecular Data
Research Indications
Anadrol is FDA-approved for the treatment of anemias caused by deficient red cell production. It stimulates erythropoietin production and has been used in patients with bone marrow failure syndromes who are not candidates for transplant.
Prior to the widespread availability of recombinant erythropoietin (EPO), oxymetholone was a primary treatment for renal anemia. It remains a secondary option in resource-limited settings.
Used to support red blood cell production in patients with myelofibrosis and other myeloproliferative disorders causing anemia.
In performance contexts, Anadrol is considered the most effective oral steroid for rapid weight gain. Users commonly report 10-15+ pounds in the first 2-3 weeks, though a significant portion is water and glycogen. Lean tissue gains are substantial when combined with adequate protein intake and training.
Dramatic increases in strength across all compound lifts, often within the first 7-10 days. Anadrol is frequently used as a kickstart compound at the beginning of injectable cycles to provide immediate performance gains while longer-estered injectables reach peak levels.
Oxymetholone has been studied and used off-label for the treatment of weight loss and muscle wasting in HIV-positive patients, showing significant improvements in lean body mass.
Used in clinical settings to combat severe muscle wasting from chronic illness, malnutrition, or prolonged hospitalization.
Dosing Protocols
Anadrol is administered exclusively as an oral tablet. The 17-alpha alkylation allows it to survive first-pass hepatic metabolism and achieve oral bioavailability, but this structural modification is the primary driver of its hepatotoxicity. Tablets are typically available in 25 mg and 50 mg strengths. Due to its short half-life of approximately 8-9 hours, some users split the daily dose into two administrations for more stable blood levels, though single daily dosing is also common.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative / Beginner | 25-50 mg/day | Once daily or split into two doses | Oral |
| Standard Performance Enhancement | 50 mg/day | Once daily or split 25 mg twice daily | Oral |
| Advanced / High Dose | 100 mg/day | Split into two doses of 50 mg | Oral |
| Medical / Anemia Treatment | 1-5 mg/kg/day | Daily | Oral |
Protocol Variations
Multiple approaches exist - compare before choosing
Different sources recommend different protocols for this peptide. Review each approach and consider your goals, tolerance, and experience level before choosing.
Cycle Kickstart
TraditionalSource: Common Performance Protocol
"Use Anadrol for the first 4 weeks of a longer injectable cycle to provide immediate mass and strength gains while the injectable testosterone or other compounds reach full saturation."
The most common performance use pattern. Anadrol is added to the first 4 weeks of a 12-16 week injectable cycle (typically testosterone-based). The oral compound delivers rapid size and strength from day one, creating a motivating and productive early phase while the injectable base builds toward peak levels.
Key Points
- Immediate results within the first week of the cycle
- Transition to injectable-only after week 4 maintains momentum
- Total cycle hepatic load is limited by the short oral window
- Strength and mass gained during the kickstart phase are largely retained if training and diet remain consistent
Dosing Schedule
Low-Dose Protocol
AlternativeSource: Conservative Approach
"Maximize the benefit-to-risk ratio by using the lowest effective dose, prioritizing health markers while still achieving meaningful gains."
A growing number of experienced users advocate for 25 mg/day as a sweet spot that provides 70-80% of the results of 50 mg/day with substantially fewer side effects, particularly reduced liver stress, less water retention, and preserved appetite. This approach is especially useful for users who are sensitive to Anadrol's side effects or who want to extend the cycle to 6 weeks.
Key Points
- Significantly reduced liver stress compared to 50-100 mg doses
- Less water retention and bloating
- Better appetite preservation - a key advantage since appetite suppression limits caloric intake
- Can potentially extend cycle duration to 6 weeks with careful liver monitoring
- Still produces impressive strength and size gains for most users
Dosing Schedule
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Significant water retention and bloating (estrogenic, not aromatase-mediated)
- Elevated blood pressure (fluid volume and RBC increase)
- Severe liver stress and elevated liver enzymes (AST/ALT)
- Back pumps and lower back pain during exercise
- Headaches (often blood pressure-related)
- Appetite suppression (paradoxical for a mass-building compound)
- Lethargy and fatigue (hepatic strain-related)
- Acne and oily skin
- Suppression of natural testosterone production
Stop Signs - Discontinue if:
- Yellowing of skin or eyes (jaundice - immediate discontinuation required)
- Severe persistent right upper quadrant abdominal pain (liver distress)
- Dark urine with pale stools (cholestasis)
- Severe headaches unresponsive to treatment (potential hypertensive crisis)
- Blood in urine or stools
- Chest pain or shortness of breath (cardiovascular event or pulmonary embolism)
- Rapid or extreme swelling in extremities
Contraindications
- Pre-existing liver disease or significantly elevated liver enzymes
- Prostate cancer or breast cancer in males
- Nephrotic phase of nephritis
- Hypercalcemia (Anadrol can exacerbate calcium levels)
- Pregnancy (Category X - causes virilization of the female fetus)
- Known hypersensitivity to oxymetholone
- Concurrent use of other 17-alpha alkylated oral steroids (compounded liver toxicity)
Quality Checklist
Good Signs
- Pharmaceutical-grade tablets from a licensed manufacturer (e.g., Anadrol-50 by Unimed/Alaven)
- Consistent tablet weight and uniform appearance
- Proper packaging with lot number, expiration date, and dosage clearly labeled
- Third-party lab testing confirming identity and dosage accuracy
- Purchased through a licensed pharmacy with valid prescription
Warning Signs
- Underground lab product without pharmaceutical-grade verification
- Tablets with inconsistent size, color, or crumbling
- Dosage claims above 50 mg per tablet (non-standard for pharmaceutical products)
- No third-party testing available
Bad Signs
- Tablets with no markings, labeling, or identifiable manufacturer
- Product testing reveals incorrect compound or contamination
- Capsules instead of pressed tablets (higher risk of inaccurate dosing from UGL sources)
- Expired product or product stored in improper conditions
- Severe and unexpected side effects suggesting contamination or mislabeling
References
- Oxymetholone therapy in aplastic and other refractory anemiasAlexanian, R., Nadell, J., Alfrey, A.Blood (1972)
Early clinical study demonstrating the efficacy of oxymetholone in stimulating erythropoiesis in patients with aplastic anemia and other refractory anemias, establishing the basis for its FDA approval in hematological indications.
- Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infectionHengge, U.R., Stocks, K., Wiehler, H., et al.British Journal of Nutrition (2003)
Randomized controlled trial showing that oxymetholone at 100-150 mg/day significantly increased body weight and lean body mass in HIV-positive patients with wasting, with acceptable hepatic safety profiles over the 16-week study period.
- The effects of oxymetholone on body composition in male HIV-infected patientsHengge, U.R., Stocks, K., Faulkner, S., et al.Annals of Pharmacotherapy (2004)
Follow-up analysis confirming significant increases in lean body mass and appetite in HIV-positive men treated with oxymetholone, with liver enzyme elevations that returned to baseline after discontinuation.
- Hepatic effects of 17-alpha-alkylated anabolic-androgenic steroidsNadell, J., Kosek, J.Clinical Pharmacology & Therapeutics (1977)
Characterized the hepatotoxic effects of 17-alpha alkylated steroids including oxymetholone, documenting cholestatic jaundice, peliosis hepatis, and hepatocellular damage with prolonged administration, establishing the rationale for limiting cycle duration.
- Oxymetholone: a review of its pharmacology and clinical efficacy in the treatment of anemiasPavlatos, A.M., Fultz, O., Monberg, M.J., Vooturi, A.Clinical Therapeutics (2001)
Comprehensive review of oxymetholone's pharmacology, pharmacokinetics, and clinical applications in anemia treatment. Noted its potent erythropoietic effects and summarized safety data including dose-dependent hepatotoxicity and cardiovascular lipid alterations.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.